pharma · Nasopharyngeal Carcinoma · Safety of Almonertinib
Sun Yat-sen University
Sun Yat-sen University clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 广州市新港西路135号, CN
- Employees
- 3,680
- Programs
- 19
- Drugs
- 25
- Patents
- 0
Sun Yat-sen University projects
9 ClinicalTrials.gov programs sponsored by Sun Yat-sen University.
Sun Yat-sen University has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Almonertinib
Sun Yat-sen University
Safety of Almonertinib
1 trial -
Bone marrow mesenchymal stem cells (low dose)
Sun Yat-sen University
Acute-On-Chronic Liver Failure
1 trial -
Chidamide
Sun Yat-sen University
Peripheral T-cell Lymphoma
1 trial -
Online adaptive SBRT
Sun Yat-sen University
Adaptive Radiotherapy
1 trial -
Probiotics Compound (Biolosion)
Sun Yat-sen University
Advanced Urothelial Carcinoma
1 trial -
Pucotenlimab
Sun Yat-sen University
Colorectal Cancer (CRC)
1 trial -
Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
Sun Yat-sen University
Locally Advanced Pancreatic Cancer
1 trial -
TPC induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
furmonertinib
Sun Yat-sen University
Non-small Cell Lung Cancer Metastatic
1 trial
Frequently asked questions
How many clinical projects does Sun Yat-sen University have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.